» Articles » PMID: 16096645

Acetylation of HIV-1 Integrase by P300 Regulates Viral Integration

Overview
Journal EMBO J
Date 2005 Aug 13
PMID 16096645
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

Integration of HIV-1 into the human genome, which is catalyzed by the viral protein integrase (IN), preferentially occurs near transcriptionally active genes. Here we show that p300, a cellular acetyltransferase that regulates chromatin conformation through the acetylation of histones, also acetylates IN and controls its activity. We have found that p300 directly binds IN both in vitro and in the cells, as also specifically demonstrated by fluorescence resonance energy transfer technique analysis. This interaction results in the acetylation of three specific lysines (K264, K266, K273) in the carboxy-terminus of IN, a region that is required for DNA binding. Acetylation increases IN affinity to DNA, and promotes the DNA strand transfer activity of the protein. In the context of the viral replication cycle, point mutations in the IN acetylation sites abolish virus replication by specifically impairing its integration capacity. This is the first demonstration that HIV-1 IN activity is specifically regulated by post-translational modification.

Citing Articles

Involvement of Human Cellular Proteins and Structures in Realization of the HIV Life Cycle: A Comprehensive Review, 2024.

Schemelev A, Davydenko V, Ostankova Y, Reingardt D, Serikova E, Zueva E Viruses. 2024; 16(11).

PMID: 39599797 PMC: 11599013. DOI: 10.3390/v16111682.


The Immune Modulatory Role of TIF1 Proteins.

Zhu Q, Xiao Y Adv Exp Med Biol. 2024; 1466:89-99.

PMID: 39546137 DOI: 10.1007/978-981-97-7288-9_6.


Help or Hinder: Protein Host Factors That Impact HIV-1 Replication.

Moezpoor M, Stevenson M Viruses. 2024; 16(8).

PMID: 39205255 PMC: 11360189. DOI: 10.3390/v16081281.


Triple lysine and nucleosome-binding motifs of the viral IE19 protein are required for human cytomegalovirus S-phase infections.

Maliano M, Yetming K, Kalejta R mBio. 2024; 15(6):e0016224.

PMID: 38695580 PMC: 11237493. DOI: 10.1128/mbio.00162-24.


A Canadian Survey of Research on HIV-1 Latency-Where Are We Now and Where Are We Heading?.

Abdalla A, Guajardo-Contreras G, Mouland A Viruses. 2024; 16(2).

PMID: 38400005 PMC: 10891605. DOI: 10.3390/v16020229.


References
1.
Lutzke R, Vink C, Plasterk R . Characterization of the minimal DNA-binding domain of the HIV integrase protein. Nucleic Acids Res. 1994; 22(20):4125-31. PMC: 331899. DOI: 10.1093/nar/22.20.4125. View

2.
Engelman A . In vivo analysis of retroviral integrase structure and function. Adv Virus Res. 1999; 52:411-26. DOI: 10.1016/s0065-3527(08)60309-7. View

3.
Chun T, Stuyver L, Mizell S, Ehler L, Mican J, Baseler M . Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997; 94(24):13193-7. PMC: 24285. DOI: 10.1073/pnas.94.24.13193. View

4.
Carteau S, Hoffmann C, Bushman F . Chromosome structure and human immunodeficiency virus type 1 cDNA integration: centromeric alphoid repeats are a disfavored target. J Virol. 1998; 72(5):4005-14. PMC: 109628. DOI: 10.1128/JVI.72.5.4005-4014.1998. View

5.
Marzio G, Tyagi M, Gutierrez M, Giacca M . HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc Natl Acad Sci U S A. 1998; 95(23):13519-24. PMC: 24851. DOI: 10.1073/pnas.95.23.13519. View